vs
Side-by-side financial comparison of RHYTHM PHARMACEUTICALS, INC. (RYTM) and COMSCORE, INC. (SCOR). Click either name above to swap in a different company.
COMSCORE, INC. is the larger business by last-quarter revenue ($93.5M vs $57.3M, roughly 1.6× RHYTHM PHARMACEUTICALS, INC.). COMSCORE, INC. runs the higher net margin — 3.2% vs -83.0%, a 86.2% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs -1.5%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 3.8%).
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
Comscore, Inc. is an American-based global media measurement and analytics company providing marketing data and analytics to enterprises, advertising agencies, brand marketers, and publishers.
RYTM vs SCOR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $57.3M | $93.5M |
| Net Profit | $-47.5M | $3.0M |
| Gross Margin | 91.6% | 41.0% |
| Operating Margin | -82.2% | 7.0% |
| Net Margin | -83.0% | 3.2% |
| Revenue YoY | 36.9% | -1.5% |
| Net Profit YoY | -9.6% | -3.7% |
| EPS (diluted) | $-0.73 | $9.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $57.3M | $93.5M | ||
| Q3 25 | $51.3M | $88.9M | ||
| Q2 25 | $48.5M | $89.4M | ||
| Q1 25 | $32.7M | $85.7M | ||
| Q4 24 | $41.8M | $94.9M | ||
| Q3 24 | $33.3M | $88.5M | ||
| Q2 24 | $29.1M | $85.8M | ||
| Q1 24 | $26.0M | $86.8M |
| Q4 25 | $-47.5M | $3.0M | ||
| Q3 25 | $-52.9M | $453.0K | ||
| Q2 25 | $-46.6M | $-9.5M | ||
| Q1 25 | $-49.5M | $-4.0M | ||
| Q4 24 | $-43.3M | $3.1M | ||
| Q3 24 | $-43.6M | $-60.6M | ||
| Q2 24 | $-32.3M | $-1.7M | ||
| Q1 24 | $-141.4M | $-1.1M |
| Q4 25 | 91.6% | 41.0% | ||
| Q3 25 | 89.3% | 40.6% | ||
| Q2 25 | 88.6% | 40.6% | ||
| Q1 25 | 88.8% | 39.6% | ||
| Q4 24 | 90.9% | 42.4% | ||
| Q3 24 | 88.5% | 41.2% | ||
| Q2 24 | 89.9% | 39.5% | ||
| Q1 24 | 89.2% | 42.3% |
| Q4 25 | -82.2% | 7.0% | ||
| Q3 25 | -102.6% | 1.9% | ||
| Q2 25 | -93.4% | -1.9% | ||
| Q1 25 | -143.7% | -2.4% | ||
| Q4 24 | -98.6% | 4.1% | ||
| Q3 24 | -132.0% | -67.4% | ||
| Q2 24 | -139.2% | -2.2% | ||
| Q1 24 | -538.7% | -2.2% |
| Q4 25 | -83.0% | 3.2% | ||
| Q3 25 | -103.1% | 0.5% | ||
| Q2 25 | -96.1% | -10.6% | ||
| Q1 25 | -151.4% | -4.7% | ||
| Q4 24 | -103.6% | 3.3% | ||
| Q3 24 | -131.2% | -68.5% | ||
| Q2 24 | -110.9% | -2.0% | ||
| Q1 24 | -544.4% | -1.2% |
| Q4 25 | $-0.73 | $9.50 | ||
| Q3 25 | $-0.82 | $-0.86 | ||
| Q2 25 | $-0.75 | $-2.73 | ||
| Q1 25 | $-0.81 | $-1.66 | ||
| Q4 24 | $-0.71 | $-0.47 | ||
| Q3 24 | $-0.73 | $-12.79 | ||
| Q2 24 | $-0.55 | $-1.19 | ||
| Q1 24 | $-2.35 | $-1.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $388.9M | $23.6M |
| Total DebtLower is stronger | — | $41.5M |
| Stockholders' EquityBook value | $139.1M | $111.4M |
| Total Assets | $480.2M | $407.7M |
| Debt / EquityLower = less leverage | — | 0.37× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $388.9M | $23.6M | ||
| Q3 25 | $416.1M | $26.7M | ||
| Q2 25 | $291.0M | $26.0M | ||
| Q1 25 | $314.5M | $31.0M | ||
| Q4 24 | $320.6M | $29.9M | ||
| Q3 24 | $298.4M | $20.0M | ||
| Q2 24 | $319.1M | $14.7M | ||
| Q1 24 | $201.2M | $18.7M |
| Q4 25 | — | $41.5M | ||
| Q3 25 | — | $41.4M | ||
| Q2 25 | — | $41.3M | ||
| Q1 25 | — | $41.3M | ||
| Q4 24 | — | $41.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $139.1M | $111.4M | ||
| Q3 25 | $148.8M | $-26.3M | ||
| Q2 25 | $-11.9M | $-21.7M | ||
| Q1 25 | $18.9M | $-13.5M | ||
| Q4 24 | $21.7M | $-8.3M | ||
| Q3 24 | $11.2M | $-2.7M | ||
| Q2 24 | $39.3M | $45.8M | ||
| Q1 24 | $61.6M | $51.4M |
| Q4 25 | $480.2M | $407.7M | ||
| Q3 25 | $506.9M | $406.9M | ||
| Q2 25 | $372.7M | $415.9M | ||
| Q1 25 | $386.7M | $421.5M | ||
| Q4 24 | $392.3M | $430.2M | ||
| Q3 24 | $363.6M | $412.5M | ||
| Q2 24 | $381.8M | $474.1M | ||
| Q1 24 | $258.7M | $477.7M |
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-25.4M | $3.2M |
| Free Cash FlowOCF − Capex | — | $2.9M |
| FCF MarginFCF / Revenue | — | 3.1% |
| Capex IntensityCapex / Revenue | — | 0.3% |
| Cash ConversionOCF / Net Profit | — | 1.07× |
| TTM Free Cash FlowTrailing 4 quarters | — | $21.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-25.4M | $3.2M | ||
| Q3 25 | $-26.6M | $9.5M | ||
| Q2 25 | $-23.3M | $932.0K | ||
| Q1 25 | $-40.4M | $9.1M | ||
| Q4 24 | $-18.8M | $-10.0M | ||
| Q3 24 | $-25.2M | $12.5M | ||
| Q2 24 | $-29.1M | $8.7M | ||
| Q1 24 | $-40.7M | $6.9M |
| Q4 25 | — | $2.9M | ||
| Q3 25 | — | $9.4M | ||
| Q2 25 | — | $787.0K | ||
| Q1 25 | — | $8.7M | ||
| Q4 24 | — | $-10.3M | ||
| Q3 24 | — | $12.4M | ||
| Q2 24 | — | $8.5M | ||
| Q1 24 | — | $6.6M |
| Q4 25 | — | 3.1% | ||
| Q3 25 | — | 10.5% | ||
| Q2 25 | — | 0.9% | ||
| Q1 25 | — | 10.1% | ||
| Q4 24 | — | -10.8% | ||
| Q3 24 | — | 14.0% | ||
| Q2 24 | — | 10.0% | ||
| Q1 24 | — | 7.6% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 0.3% |
| Q4 25 | — | 1.07× | ||
| Q3 25 | — | 20.96× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -3.19× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RYTM
Segment breakdown not available.
SCOR
| Transferred Over Time | $77.1M | 83% |
| Research Insight Solutions | $14.6M | 16% |
| Related Party | $2.5M | 3% |
